PUBLIC CONTRACT · 2022

Aquisição de BEVACIZUMAB BIO 25MGML 16ML SOL INJ ao Laboratorio Amgen para o HFF para o ano de 2022

Contract value
€39,736.00
Signed on
6 October 2022
Procedure
Direct award, general (Ajuste Direto Regime Geral)

This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.

Record 9565939

PUBLISHED SUBJECT

Aquisição de BEVACIZUMAB BIO 25MGML 16ML SOL INJ ao Laboratorio Amgen para o HFF para o ano de 2022

Parties involved

Place of performance
Portugal, Lisboa, Amadora
NUTS region
Not stated

WHO BID

Awardee and competitors

Companies that IMPIC lists as the awardee and as competitors in this procedure.

Awardee
Amgen-Biofarmaceutica, Lda. · Tax ID 502942959

Values and timeline

Contract price
€39,736.00
Procedure base price
€62,432.00
Total effective price
Not reported on Portal BASE
Publication date
18 November 2022
Award date
27 September 2022
Signing date
6 October 2022
Performance period
103 days

The contract price is the value agreed in the contract, not the amount paid.

Procedure and framework

Contract type
Aquisição de bens móveis
Award criterion
Monofator
CPV code
33600000-6 - Produtos farmacêuticos
Legal basis
Artigo 24.º, n.º 1, alínea e), subalínea ii) do Código dos Contratos Públicos
Regime
Código dos Contratos Públicos ( DL 111-B/2017 )
Framework agreement
Not stated
Centralised procedure
No
Environmental criterion
No
Notice
Not stated
Procedure identifier
6073218

Compare with other contracts

Search the same body, supplier, place or type of service to understand the context of the published index.

← Back to contracts